Drug Delivery Report

Welcome to drugdeliveryreport.com!

Established for over 11 years, the Drug Delivery Report is relied upon within the industry as the main method of independently assessing drug delivery partners to enable drug delivery deal making. drugdeliveryreport.com has been developed to ensure that you can access up-to-the-minute drug delivery deal making opportunities as well as key facts and trends affecting the drug delivery market. 

Market news and trends

In August and September 2007, 64 drug delivery deals were recorded in PharmaDeals® Agreements, 28 of which occurred in August. Licensing deals were the most prolific of these, with 23 signed over the 2-month period. One of these is a deal between BioDelivery Sciences International (BDSI) and Meda (Deal no. 28232) for the marketing of BEMA™ Fentanyl in the US, Canada and Mexico. This patented product has a unique delivery system designed to deliver fentanyl for the treatment of breakthrough pain in cancer patients. BEMA™ Fentanyl consists of a small, dissolvable, polymer disc, formulated with the opioid narcotic fentanyl, for application to the buccal (inner lining of the cheek) membranes. This deal is worth US$90 M, and is the largest licensing deal in this period concerned. The US$90 M includes an upfront payment of US$30 M made by Meda to BDSI on closing of the deal, US$30 M payable on product approval by the US FDA, and US$30 M in sales milestones made to Meda. BDSI has since received the initial (upfront) non-refundable milestone payment of US$30 M. The companies will also collaborate on development for expanding the indication for BEMA™ Fentanyl.

Featured article - New-Generation Auto-Injectors: Completing the Scale of Convenience for Self-injection

The market for pens and auto-injectors continues to grow for the convenient self-injection of biopharmaceuticals. Pre-filled syringes are becoming increasingly widespread for self-injection and auto-injectors are helping to simplify their use in new and existing therapeutic areas. In this article, Ian Thompson of Ypsomed AG discusses the history of self-injection devices over the last twenty years and the development of new and sophisticated devices, including Ypsomed's Auto-Injector, which works with the UltraSafe® Delivery System. Ian Thompson shows how such devices can be created in a variety of customised designs in order to meet the needs of a wide range of patient groups, safely and reliably.